Rowan Chapman joined MDV in 2001. Through her relationships with industry and academic leaders advancing the fields of personalized medicine, drug discovery technology and regenerative medicine she both sources new life sciences investments and works to develop and grow MDV life sciences companies including Artemis Health, Pacific Biosciences, Adamas Pharmaceuticals and ParAllele BioScience (acquired by Affymetrix). Rowan is also a member of the Personalized Medicine Coalition.
Prior to joining MDV she held the position of director of business development at Rosetta Inpharmatics (acquired by Merck) where she established collaborative partnerships with organizations in the pharmaceutical, agricultural and biotech fields as well as among various research institutions. Previously, Rowan held the position of marketing manager at Incyte Genomics.
Rowan holds a Ph.D. in cellular and molecular biology from the MRC... See More